{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:33:31Z","timestamp":1794000811722,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM144450"],"award-info":[{"award-number":["R01GM144450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejmech.2025.117576","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T01:55:02Z","timestamp":1743558902000},"page":"117576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Advances and challenges in immunosuppressive antibody drug conjugates"],"prefix":"10.1016","volume":"291","author":[{"given":"Aiman A.","family":"Yaseen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-7018","authenticated-orcid":false,"given":"L. Nathan","family":"Tumey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117576_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.117576_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117576_bib3","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/acs.molpharmaceut.9b00063","article-title":"Antigen-drug conjugates as a novel therapeutic class for the treatment of antigen-specific autoimmune disorders","volume":"16","author":"Pickens","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.117576_bib4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates - an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117576_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody-drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117576_bib6","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2025.117576_bib7","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2025.117576_bib8","article-title":"Budesonide for maintenance of remission in Crohn's disease","volume":"2014","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2025.117576_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000359984","article-title":"Glucocorticoids","volume":"100","author":"Barnes","year":"2014","journal-title":"Chem. Immunol. Allergy"},{"key":"10.1016\/j.ejmech.2025.117576_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.117576_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2013.01.026","article-title":"Optimized glucocorticoid therapy: teaching old drugs new tricks","volume":"380","author":"Strehl","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.117576_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejmech.2025.117576_bib13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2025.117576_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.21984","article-title":"Population-based assessment of adverse events associated with long-term glucocorticoid use","volume":"55","author":"Curtis","year":"2006","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ejmech.2025.117576_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2025.117576_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2025.117576_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2010.02.040","article-title":"Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review","volume":"78","author":"Ruyssen-Witrand","year":"2011","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.ejmech.2025.117576_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00556","article-title":"Small-Molecule Immunosuppressive drugs and therapeutic immunoglobulins differentially inhibit NK cell effector functions in vitro","volume":"10","author":"Pradier","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.117576_bib19","unstructured":"R. Ruiz, A.D. Kirk, Long-Term ToxiciTy of Immunosuppressive Therapy, ."},{"key":"10.1016\/j.ejmech.2025.117576_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.ejmech.2025.117576_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/conmed-2018-000004","article-title":"IL-6: to immunity and beyond","volume":"2","author":"Choy","year":"2018","journal-title":"Considerations in Medicine"},{"key":"10.1016\/j.ejmech.2025.117576_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117576_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ejmech.2025.117576_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.117576_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates - an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117576_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071807","article-title":"An Overview of the development and preclinical evaluation of antibody\u2013drug conjugates for non-oncological applications","volume":"15","author":"Pal","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.117576_bib27","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1021\/acs.jmedchem.2c01579","article-title":"Discovery of ABBV-3373, an anti-TNF glucocorticoid receptor modulator immunology antibody drug conjugate","volume":"65","author":"Hobson","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/19420862.2017.1304869","article-title":"Transmembrane TNF-dependent uptake of anti-TNF antibodies","volume":"9","author":"Deora","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2025.117576_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0168-8278(00)80222-6","article-title":"Dexamethasone coupled to albumin is selectively taken up by rat nonparenchymal liver cells and attenuates LPS-induced activation of hepatic cells","volume":"32","author":"Melgert","year":"2000","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.117576_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/jhep.2001.27805","article-title":"Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats","volume":"34","author":"Melgert","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.117576_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13090245","article-title":"Antibody\u2013drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117576_bib32","author":"Everts"},{"key":"10.1016\/j.ejmech.2025.117576_bib33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/mt.2012.103","article-title":"Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone","volume":"20","author":"Graversen","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.117576_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0b013e31828a45ef","article-title":"Targeting dexamethasone to macrophages in a porcine endotoxemic model","volume":"41","author":"Granfeldt","year":"2013","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejmech.2025.117576_bib35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amsu.2015.09.001","article-title":"Anti-CD163-dexamethasone protects against apoptosis after ischemia\/reperfusion injuries in the rat liver","volume":"4","author":"M\u00f8ller","year":"2015","journal-title":"Annals of Medicine and Surgery"},{"key":"10.1016\/j.ejmech.2025.117576_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2016.11.004","article-title":"Antibody-directed glucocorticoid targeting to CD163 in M2-type macrophages attenuates fructose-induced liver inflammatory changes","volume":"4","author":"Svendsen","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejmech.2025.117576_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117576_bib38","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117576_bib39","unstructured":"C.P. Jackson, S. Fang, S.R. Benjamin, T. Alayi, Y. Hathout, S.M. Gillen, J.P. Handel, B.M. Brems, J.M. Howe, L.N. Tumey, Evaluation of an ester-linked immunosuppressive payload: A case study in understanding the stability and cleavability of ester-containing ADC linkers, https:\/\/ssrn.com\/abstract=4110438."},{"key":"10.1016\/j.ejmech.2025.117576_bib40","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/jacs.5b12547","article-title":"Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates","volume":"138","author":"Kern","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117576_bib41","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1021\/acs.bioconjchem.6b00337","article-title":"Novel phosphate modified cathepsin B linkers: improving aqueous solubility and enhancing payload scope of ADCs","volume":"27","author":"Kern","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib42","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.bioconjchem.3c00354","article-title":"Self-immolative carbamate linkers for CD19-budesonide antibody-drug conjugates","volume":"34","author":"Marvin","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib43","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.117576_bib44","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117576_bib45","unstructured":"C.P. Jackson, S. Fang, S.R. Benjamin, T. Alayi, Y. Hathout, S.M. Gillen, J.P. Handel, B.M. Brems, J.M. Howe, L.N. Tumey, Evaluation of an ester-linked immunosuppressive payload: A case study in understanding the stability and cleavability of ester-containing ADC linkers, https:\/\/ssrn.com\/abstract=4110438."},{"key":"10.1016\/j.ejmech.2025.117576_bib46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1208\/s12248-017-0083-7","article-title":"Site selection: a case study in the identification of optimal cysteine engineered antibody drug conjugates","volume":"19","author":"Tumey","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2025.117576_bib47","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1021\/acs.molpharmaceut.9b00323","article-title":"Thiolation of Q295: site-specific conjugation of hydrophobic payloads without the need for genetic engineering","volume":"16","author":"Benjamin","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.117576_bib48","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1039\/D3MD00336A","article-title":"ValCitGlyPro-dexamethasone antibody conjugates selectively suppress the activation of human monocytes","volume":"14","author":"Howe","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib49","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1021\/acs.bioconjchem.8b00312","article-title":"Development of anti-CD74 antibody-drug conjugates to target glucocorticoids to immune cells","volume":"29","author":"Brandish","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib50","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2025.117576_bib51","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc0502917","article-title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","volume":"17","author":"Doronina","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib52","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1021\/acs.jmedchem.1c02099","article-title":"Design and development of glucocorticoid receptor modulators as immunology antibody-drug conjugate payloads","volume":"65","author":"Hobson","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.6b00195","article-title":"Optimization of tubulysin antibody-drug conjugates: a case study in addressing ADC metabolism","volume":"7","author":"Nathan Tumey","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117576_bib54","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/bc500357n","article-title":"Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy","volume":"25","author":"Tumey","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib55","series-title":"Glucocorticoid Receptor Agonist and Immunoconjugates Thereof","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117576_bib56","doi-asserted-by":"crossref","first-page":"11958","DOI":"10.1021\/acs.jmedchem.1c00541","article-title":"Development of novel glucocorticoids for use in antibody-drug conjugates for the treatment of inflammatory diseases","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib57","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an Overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejmech.2025.117576_bib58","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1021\/acs.jmedchem.3c00794","article-title":"Optimization of drug-linker to enable long-term storage of antibody-drug conjugate for subcutaneous dosing","volume":"66","author":"Hobson","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib59","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1021\/acs.jmedchem.3c01174","article-title":"Discovery of ABBV-154, an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (iADC)","volume":"66","author":"Hobson","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib60","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/bc7004329","article-title":"Contribution of linker stability to the activities of anticancer immunoconjugates","volume":"19","author":"Alley","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib61","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/pip-discontinuation\/adalimumab-conjugated-4s-4-2-2-bromoacetamidoacetamido-5abbv-154-notification-discontinuation-paediatric-development-which-covered-agreed-pip-decision_en.pdf, ."},{"key":"10.1016\/j.ejmech.2025.117576_bib62","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1124\/dmd.108.022137","article-title":"Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid","volume":"36","author":"Hughes","year":"2008","journal-title":"humans, Drug Metabolism and Disposition"},{"key":"10.1016\/j.ejmech.2025.117576_bib63","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c00598","article-title":"Anti-TNF thioester glucocorticoid antibody-drug conjugate fully inhibits inflammation with minimal effect on systemic corticosterone levels in a mouse arthritis model","author":"Marvin","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117576_bib64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117576_bib65","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-11-26","article-title":"The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma","volume":"11","author":"Singh","year":"2010","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejmech.2025.117576_bib66","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/mt.2016.175","article-title":"Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate","volume":"24","author":"Yu","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.117576_bib67","doi-asserted-by":"crossref","first-page":"520","DOI":"10.54203\/scil.2023.wvj55","article-title":"Carrageenan-induced acute inflammation on back-skin of mice: histopathological features, number of inflammatory cells, and expression of COX-2, COX-1, and IL-6","volume":"13","author":"Widyarini","year":"2023","journal-title":"World's Vet. J. (WVJ)"},{"key":"10.1016\/j.ejmech.2025.117576_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12248","article-title":"Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases","volume":"176","author":"Patterson","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejmech.2025.117576_bib69","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/jacs.5b00620","article-title":"An immunosuppressive antibody-drug conjugate","volume":"137","author":"Wang","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117576_bib70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bcp.15888","article-title":"A first-in-human study of the novel immunology antibody\u2013drug conjugate, ABBV-3373, in healthy participants","volume":"90","author":"D'Cunha","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117576_bib71","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","article-title":"Efficacy and safety of ABBV-3373, a novel anti\u2013tumor necrosis factor glucocorticoid receptor modulator antibody\u2013drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-control","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.ejmech.2025.117576_bib72","unstructured":"https:\/\/news.abbvie.com\/2020-06-10-Novel-Antibody-Drug-Conjugate-ABBV-3373-Shows-Improvement-in-Disease-Activity-in-Phase-2a-Study-of-Patients-with-Rheumatoid-Arthritis, ."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425003411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:39:22Z","timestamp":1778042362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425003411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":72,"alternative-id":["S0223523425003411"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117576","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and challenges in immunosuppressive antibody drug conjugates","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117576"}}